Fatty Acid Synthesis Pathway Genetic Variants and Clinical Outcome of Non-Small Cell Lung Cancer Patients after Surgery

被引:14
|
作者
Jin, Xin [1 ,2 ,3 ]
Zhang, Ke-Jin [5 ,6 ]
Guo, Xu [2 ,3 ]
Myers, Ronald [6 ]
Ye, Zhong [6 ]
Zhang, Zhi-Pei [4 ]
Li, Xiao-Fei [4 ]
Yang, Hu-Shan [6 ]
Xing, Jin-Liang [2 ,3 ]
机构
[1] Fourth Mil Med Univ, Xijing Hosp, Dept Pharm, Xian 710032, Peoples R China
[2] Fourth Mil Med Univ, Tangdu Hosp, Cell Engn Res Ctr, State Key Lab Canc Biol, Xian 710032, Peoples R China
[3] Fourth Mil Med Univ, Tangdu Hosp, Dept Cell Biol, Xian 710032, Peoples R China
[4] Fourth Mil Med Univ, Tangdu Hosp, Dept Thorac Surg, Xian 710032, Peoples R China
[5] NW Univ Xian, Coll Life Sci, Xian 710069, Peoples R China
[6] Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Med Oncol, Div Populat Sci, Philadelphia, PA 19107 USA
关键词
De novo lipogenesis; FASN; non-small cell lung cancer; prognosis; single nucleotide polymorphisms; ATP-CITRATE LYASE; THERAPEUTIC IMPLICATIONS; SYNTHASE EXPRESSION; PREDICTOR; SURVIVAL; SNPS; POLYMORPHISMS; INHIBITION; IMPACT; GROWTH;
D O I
10.7314/APJCP.2014.15.17.7097
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Over-expression of de novo lipogenesis (DNL) genes is associated with the prognosis of various types of cancers. However, the effects of single nucleotide polymorphisms (SNPs) in these genes on recurrence and survival of non-small cell lung cancer (NSCLC) patients after surgery are still unknown. In this study, a total of 500 NSCLC patients who underwent surgery treatment were included. Eight SNPs in 3 genes (ACACA, FASN and ACLY) of the DNL pathway were examined using the Sequenom iPLEX genotyping system. Multivariate Cox proportional hazards regression and Kaplan-Meier curves were used to analyze the association of SNPs with patient survival and tumour recurrence. We found that two SNPs in the FASN gene were significantly associated with the recurrence of NSCLC. SNP rs4246444 had a significant association with lung cancer recurrence under additive model (hazard ratio [HR], 0.82; 95% confidence interval [95% CI], 0.67-1.00; p=0.05). Under the dominant model, rs4485435 exhibited a significant association with recurrence (HR, 0.75; 95% CI, 0.56-1.01; p=0.05). Additionally, SNP rs9912300 in ACLY gene was significantly associated with overall survival in lung cancer patients (HR, 1.41; 95% CI, 1.02-1.94, p=0.04) under the dominant model. Further cumulative effect analysis showed moderate dose-dependent effects of unfavorable SNPs on both survival and recurrence. Our data suggest that the SNPs in DNL genes may serve as independent prognostic markers for NSCLC patients after surgery.
引用
收藏
页码:7097 / 7103
页数:7
相关论文
共 50 条
  • [31] The prognostic value of the preoperative albumin to alkaline phosphatase ratio in patients with non-small cell lung cancer after surgery
    Zhang, Lianmin
    Zhang, Hua
    Yue, Dongsheng
    Wei, Wei
    Chen, Yulong
    Zhao, Xiaoliang
    Zhu, Jianquan
    Zhang, Bin
    Zhang, Zhenfa
    Wang, Changli
    THORACIC CANCER, 2019, 10 (07) : 1581 - 1589
  • [32] Clinical outcome of subcentimeter non-small cell lung cancer after VATS resection: Single institute experience with 424 patients
    Tsou, Kuan-Chuan
    Hsu, Hsao-Hsun
    Tsai, Tung-Ming
    Chen, Ke-Cheng
    Chen, Jin-Shing
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2020, 119 (01) : 399 - 405
  • [33] Clinical Outcome of Subcentimeter Non-Small Cell Lung Cancer After Surgical Resection: Single Institution Experience of 105 Patients
    Jiang, Wei
    Pang, Xuguang
    Xi, Junjie
    Chen, Xiaoke
    Wang, Qun
    Qian, Cheng
    Fan, Hong
    JOURNAL OF SURGICAL ONCOLOGY, 2014, 110 (03) : 233 - 238
  • [34] Role of VEGF gene polymorphisms in the clinical outcome of non-small cell lung cancer
    Chen, N.
    Ma, C. N.
    Zhao, M.
    Zhang, Y. J.
    GENETICS AND MOLECULAR RESEARCH, 2015, 14 (04) : 16006 - 16011
  • [35] Potential clinical predictors of outcome after postoperative radiotherapy of non-small cell lung cancer
    Buetof, R.
    Kirchner, K.
    Appold, S.
    Loeck, S.
    Rolle, A.
    Hoeffken, G.
    Krause, M.
    Baumann, M.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2014, 190 (03) : 263 - 269
  • [36] Genetic variants in LKB1/AMPK/mTOR pathway are associated with clinical outcomes of chemotherapy in non-small cell lung cancer
    Ha Choi, Sun
    Do, Sook Kyung
    Lee, Shin Yup
    Choi, Jin Eun
    Kang, Hyo-Gyoung
    Hong, Mi Jeong
    Lee, Jang Hyuck
    Lee, Won Kee
    Jeong, Ji Yun
    Shin, Kyung Min
    Do, Young Woo
    Lee, Eung Bae
    Park, Ji Eun
    Lee, Yong Hoon
    Seo, Hyewon
    Yoo, Seung Soo
    Lee, Jaehee
    Cha, Seung Ick
    Kim, Chang Ho
    Park, Jae Yong
    THORACIC CANCER, 2022, 13 (23) : 3322 - 3330
  • [37] Physical activity in patients with non-small cell lung cancer after lung resection
    Yanagita, Yorihide
    Arizono, Shinichi
    Tawara, Yuichi
    Oomagari, Masaki
    Machiguchi, Hikaru
    Tanahashi, Masayuki
    Katagiri, Norimasa
    Iida, Yuki
    Kozu, Ryo
    CLINICAL BIOMECHANICS, 2024, 115
  • [38] Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcome in Resected Non-Small Cell Lung Cancer Patients
    Ragusa, Mark
    Vannucci, Jacopo
    Ludovini, Vienna
    Bianconi, Fortunato
    Treggiari, Stefano
    Tofanetti, Francesca R.
    Flacco, Antonella
    Colella, Renato
    Sidoni, Angelo
    Crino, Lucio
    Puma, Francesco
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2014, 37 (04): : 343 - 349
  • [39] TSC2 genetic variant and prognosis in non-small cell lung cancer after curative surgery
    Lee, Yong Hoon
    Do, Sook Kyung
    Lee, Shin Yup
    Kang, Hyo-Gyoung
    Choi, Jin Eun
    Hong, Mi Jeong
    Lee, Jang Hyuck
    Lee, Eung Bae
    Jeong, Ji Yun
    Shin, Kyung Min
    Lee, Won Kee
    Seok, Yangki
    Cho, Sukki
    Yoo, Seung Soo
    Lee, Jaehee
    Cha, Seung Ick
    Kim, Chang Ho
    Jheon, Sanghoon
    Park, Jae Yong
    THORACIC CANCER, 2019, 10 (02) : 335 - 340
  • [40] Is prior cancer history a hindrance for non-small cell lung cancer patients to participate in clinical trials?
    Cai, Jing-Sheng
    Li, Yun
    Wang, Xun
    BMC CANCER, 2023, 23 (01)